Description
Apellis Pharmaceuticals, Inc.: Initiation Of Coverage – A Dominant Force In PNH & Nephrology Market
Apellis Pharmaceuticals, a biopharmaceutical company, recently reported its earnings for the second
quarter of 2024, presenting the progress and results for the period. The management, specifically Chief
Executive Officer Dr. Cedric Francois discussed the company’s position with its products SYFOVRE and
EMPAVELI, emphasizing SYFOVRE’s leading market position in the treatment of geographic atrophy (GA),
despite facing competitive pressures. The company expressed optimism about SYFOVRE’s robust performance in the market.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
